Business
Marvel Biosciences to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021
CALGARY, AB / ACCESSWIRE / December 3, 2021 / Marvel Biosciences (TSXV:MRVL), and its wholly...
About this update from Marvel Biosciences Corp
[{"type":"text","content":"Marvel Biosciences to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021CALGARY, AB / ACCESSWIRE / December 3, 2021 / Marvel Biosciences (TSXV:MRVL), and its wholly owned subsidiary, Marvel Biotechnology Inc., today announced that it will be presenting at the SNN Network Canada Virtual Event 2021 on Wednesday, December 8th at 2:00 PM EST. President and CSO Mark Williams will be hosting the presentation and answering questions from investors.To access the live presentation, please use the following information:SNN Network Canada Virtual Event 2021Date: Wednesday, December 8, 2021Time: 2:00 PM Eastern Time (11:00 AM Pacific Time)Webcast: https://www.webcaster4.com/Webcast/Page/2813/43699If you would like to book 1on1 investor meetings with Marvel, and to watch the company's presentation, please make sure you are registered for the virtual event here: https://canada.snn.network/signup1on1 meetings will be scheduled and conducted via private, secure video conference through the conference event platform.The SNN Network Canada Virtual Event website is available here: https://canada.snn.network/If you can't make the live presentation, all company presentations \"webcasts\" will be available directly on the conference event platform on this link under the tab \"Agenda\": https://canada.snn.network/agendaNews Compliments of AccesswireAbout Marvel Biosciences Corp.Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a \"drug redevelopment\" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compare...